119 withdrawn. 119 Phase 2, 25 Phase 1, 9 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 119 | Withdrawn 119 |
| Phase 1 | 25 | Withdrawn 25 |
| Phase 3 | 9 | Withdrawn 9 |
Follow Autoimmune Diseases: new trials by email Literature Review of Autoimmune Diseases trials Research Report on Autoimmune Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Cannabichromene Safety in Rheumatoid Arthritis Cannabichromene - Arthritis, Rheumatoid | Phase 1 / Phase 2 | Withdrawn | Crystal Lederhos Smith | 2028-07-15 | 2026-09-23 | |
| A Phase IIb Study of Nabiximols for Spasticity Due to Neuromyelitis Optica Spectrum Disorders Nabiximols, Placebo - NMO Spectrum Disorder, Spasticity, Muscle | Phase 2 | Withdrawn | Michael, Levy M.D.,Ph.D. | 2026-12-31 | 2025-07-16 | |
| C-CAR168 CAR T Cell Therapy for Refractory Autoimmune Disease C-CAR168 - Lupus Nephritis (LN) | Phase 1 / Phase 2 | Withdrawn | AbelZeta Inc. | 2026-07-01 | 2026-07-16 | |
| Study of Ianalumab in Adults With Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) Who Have Previously Benefited From Ianalumab Ianalumab - Primary Immune Thrombocytopenia, Warm Autoimmune Hemolytic Anemia | Phase 2 | Withdrawn | Novartis Pharmaceuticals | 2026-06-26 | 2026-10-15 | |
| RESET-MS: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Multiple Sclerosis CABA-201 - Relapsing Multiple Sclerosis (RMS), Progressive Multiple Sclerosis (PMS) | Phase 1 / Phase 2 | Withdrawn | Cabaletta Bio | 2026-06-01 | 2026-06-25 | |
| A Study to Evaluate Crovalimab in People With Antiphospholipid Syndrome (APS) Crovalimab, Placebo, VKA - Antiphospholipid Syndrome | Phase 2 | Withdrawn | Hoffmann-La Roche | 2026-03-16 | 2026-03-02 | |
| Intrathecal Amniotic Fluid Stem Cells for Progressive Multiple Sclerosis Amniotic fluid or placental CD117 stem cells - Multiple Sclerosis, Progressive | Phase 1 / Phase 2 | Withdrawn | Wake Forest University Health Sciences | 2026-02-01 | 2026-02-06 | |
| A Study of Nipocalimab in Adult Participants With Active Lupus Nephritis Placebo, Nipocalimab, Standard-of-care treatment - Lupus Nephritis | Phase 2 | Withdrawn | Janssen Research & Development, LLC | 2026-01-15 | 2026-02-27 | |
| HB-adMSCs vs Placebo for the Treatment of Juvenile Idiopathic Arthritis allogeneic Hope Biosciences adipose-derived mesenchymal stem cells, Normal Saline Solution 0.9% - Juvenile Idiopathic Arthritis (JIA) | Phase 2 | Withdrawn | Hope Biosciences Research Foundation | 2026-01-01 | 2026-01-07 | |
| Extension Study (Extended Access) of Syk-inhibition Using Fostamatinib to Treat Posttransplant Immune-mediated Cytopenias fostamatinib - Immune Mediated Anemia, Immune Mediated Thrombocytopenia | Phase 2 | Withdrawn | National Heart, Lung, and Blood Institute (NHLBI) | 2025-11-07 | 2025-11-10 | |
| Eculizumab For Acute Attack of Neuromyelitis Optica Spectrum Disorder Complement protein C5 inhibitor, IVMP - Neuromyelitis Optica Spectrum Disorder Attack | Phase 2 | Withdrawn | Tianjin Medical University General Hospital | 2025-09-03 | 2025-09-10 | |
| Rituximab in Chronic Inflammatory Demyelinating Polyneuropathy Rituximab - Chronic Inflammatory Demyelinating Polyneuropathy | Phase 2 | Withdrawn | University of Kansas Medical Center | 2025-07-01 | 2025-09-17 | |
| A Clinical Trial Evaluating the Safety and Efficacy of Myelin-peptide Loaded tolDC as Treatment for MS tolerogenic dendritic cells (tolDC), Standard-of-care - Multiple Sclerosis | Phase 2 | Withdrawn | University Hospital, Antwerp | 2025-04-30 | 2025-08-17 | |
| A Study of the Safety and Efficacy of Pancreatic Endocrine Cell Clusters Implanted Into the Omentum of Type 1 Diabetes Patients With Severe Hypoglycemia Allogeneic Pancreatic Endocrine Cell Clusters - Diabetes Mellitus Type 1 | Phase 1 / Phase 2 | Withdrawn | Seraxis | 2025-04-01 | 2025-10-16 | |
| Phase 1b/2a in SLE With Budoputug budoprutug - Systemic Lupus Erythematosus, SLE | Phase 1 / Phase 2 | Withdrawn | Tenet Medicines | 2025-01-01 | 2024-10-16 | |
| Evaluating Efgartigimod in Patients With Guillain-Barré Syndrome Efgartigimod Alfa-Fcab, Intravenous Immunoglobulin (IVIg) - Guillain-Barre Syndrome | Phase 2 | Withdrawn | Chafic Karam | 2024-09-10 | 2026-03-12 | |
| Diabetes Islet Preservation Immune Treatment Anti-Thymocyte Globulin (ATG), Interleukin 2, Exenatide - Diabetes Mellitus, Type 1, Hypoglycemia | Phase 1 / Phase 2 | Withdrawn | Camillo Ricordi and Jay Skyler | 2024-06-01 | 2026-01-15 | |
| A Study of Pirtobrutinib (LY3527727 [LOXO-305]) Versus Placebo in Participants With Relapsing Multiple Sclerosis Placebo, Pirtobrutinib - Relapsing Multiple Sclerosis, Multiple Sclerosis | Phase 2 | Withdrawn | Loxo Oncology, Inc. | 2024-05-01 | 2024-03-27 | |
| A Study of IMPT-514 in Active Refractory Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE) IMPT-514 - Systemic Lupus Erythematosus, Lupus Nephritis | Phase 1 / Phase 2 | Withdrawn | Lyell Immunopharma, Inc. | 2024-02-15 | 2025-02-10 | |
| Study to Assess the Safety and Efficacy of an IT Administration of SCM-010 in SPMS SCM-010 - Secondary Progressive Multiple Sclerosis (SPMS) | Phase 1 / Phase 2 | Withdrawn | Stem Cell Medicine Ltd. | 2024-02-01 | 2024-04-18 |
Showing 20 of 119. Sign in to see all of them.
Diabetes Mellitus, Type 1 (29) · Multiple Sclerosis (18) · Arthritis, Rheumatoid (16) · Diabetes Mellitus (10) · Lupus Erythematosus, Systemic (9) · Purpura, Thrombocytopenic, Idiopathic (9) · Hypoglycemia (8) · Insulin Resistance (5) · Lupus Nephritis (5) · Multiple Sclerosis, Relapsing-Remitting (5) · Graves Ophthalmopathy (4) · Multiple Sclerosis, Chronic Progressive (4) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (3) · Arthritis (3)
Immune System Diseases (117) · Nervous System Diseases (35) · Skin and Connective Tissue Diseases (35) · Autoimmune Diseases of the Nervous System (33) · Connective Tissue Diseases (31) · Demyelinating Diseases (31) · Nutritional and Metabolic Diseases (31) · Endocrine System Diseases (30) · Pathological Conditions, Signs and Symptoms (29) · Glucose Metabolism Disorders (28) · Metabolic Diseases (28) · Demyelinating Autoimmune Diseases, CNS (27) · Musculoskeletal Diseases (22) · Pathologic Processes (22)
Rituximab (7) · Cyclophosphamide (5) · Methylprednisolone (5) · Mycophenolic Acid (5) · Insulin (4) · Methods (4) · Antilymphocyte Serum (3) · Continuous Glucose Monitoring (3) · Glucagon (3) · Immunoglobulins, Intravenous (3) · Insulin Infusion Systems (3) · Methotrexate (3) · fostamatinib (3) · AMG623 peptibody (2) · Abatacept (2)
Institut de Recherches Cliniques de Montreal (5) · National Institute of Allergy and Infectious Diseases (NIAID) (5) · Novartis Pharmaceuticals (4) · GlaxoSmithKline (3) · Indiana University (3) · Anthera Pharmaceuticals (2) · Biogen (2) · Brigham and Women's Hospital (2) · Hoffmann-La Roche (2) · Iran University of Medical Sciences (2) · Janssen Research & Development, LLC (2) · Johns Hopkins University (2) · Northwestern University (2) · Rigel Pharmaceuticals (2) · Stony Brook University (2)
United States (50) · Canada (8) · United Kingdom (7) · Netherlands (4) · Australia (3) · China (3) · France (3) · Germany (3) · Belgium (2) · Czechia (2) · Iran (2) · Italy (2) · Poland (2) · Russia (2) · Spain (2)
Richard Burt, MD (3) · Jeff Bornstein, MD (2) · Michael Levy, MD, PhD (2) · Mohsen B Kashkouli, MD (2) · Patrick H Nachman, MD (2) · Adrian H Cotterell, M.D. (1) · Adrian Vella, MD (1) · Alberto Pugliese, M.D. (1) · Alejandro D. Mesples, MD (1)
PMID 12084892, PMID 14668458, PMID 14961990, PMID 15703014, PMID 16908728, PMID 17564637, PMID 22150039, PMID 22328739, PMID 22885417, PMID 23829627, PMID 24699939, PMID 30787930, PMID 32358837, PMID 32990324, PMID 34778952
P01DK058335 (2), 1UC4DK117009-01 (1), 2005 (1), 2008 (1), 2009 (1), 2015 (1), 2017 (1), 2018 (1), 2019 (1), 2025 (1), P30DK057516 (1), U01DK106993 (1)